Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue Contraction

    Question

    Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue Contraction

    Direct answer

    DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, exceeding consensus expectations of $0.36 despite a 4.1% top-line contraction. Management maintained full-year 2026 sales guidance at $3.5 billion to $3.6 billion and adjusted EPS guidance at $1.40 to $1.50, supported by 7.1% growth in Wellspect Healthcare.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue Contraction”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-q2-eps-beats-at-0-52-despite-4-1-revenue-contraction-c96be7

    EQUITY
    Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue Contraction
    DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, exceeding consensus expectations of $0.36 despite a 4.1% top-line contraction. Management maintained full-year 2026 sales guidance at $3.5 billion to $3.6 billion and adjusted EPS guidance at $1.40 to $1.50, supported by 7.1% growth in Wellspect Healthcare.
    XRAY
    Impact
    68
    SEP 9
    SIG
    83%
    XRAY
    Dentsply Sirona Q2 EPS Beats at $0.52 Despite 4.1% Revenue Contraction
    DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, exceeding consensus expectations of $0.36 despite a 4.1% top-line contraction. Management maintained full-year 2026 sales guidance at $3.5 billion to $3.6 billion and adjusted EPS guidance at $1.40 to $1.50, supported by 7.1% growth in Wellspect Healthcare.
    → An adjusted EPS beat of $0.52 versus $0.36 consensus offsets organic revenue decline of 4.1%, stabilizing XRAY forward earnings estimates around full-year $1.40 to $1.50 guidance.
    Impact
    DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, exceeding consensus expectations of $0.36 despite a 4.1% top-line contraction. Management maintained full-year 2026 sales guidance at $3.5 billion to $3.6 billion and adjusted EPS guidance at $1.40 to $1.50, supported by 7.1% growth in Wellspect Healthcare.
    Affected
    XRAY
    Transmission
    An adjusted EPS beat of $0.52 versus $0.36 consensus offsets organic revenue decline of 4.1%, stabilizing XRAY forward earnings estimates around full-year $1.40 to $1.50 guidance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYoperating margin resilience offsetting top-line contractionMixed1-5dQ2 adjusted EPS of $0.52 beat $0.36 consensus while revenue fell 4.1% YoY.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month